Currently out of the existing stock ratings of David Lebowitz, 99 are a BUY (59.64%), 42 are a HOLD (25.3%), 25 are a SELL (15.06%).

David Lebowitz

Work Performance Price Targets & Ratings Chart

Analyst David Lebowitz, currently employed at CITI, carries an average stock price target met ratio of 56.67% that have a potential upside of 40.26% achieved within 181 days.

David Lebowitz’s has documented 320 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MIRM, Mirum Pharmaceuticals at 13-Nov-2024.

Wall Street Analyst David Lebowitz

Analyst best performing recommendations are on SDGR (SCHRODINGER).
The best stock recommendation documented was for SDGR (SCHRODINGER) at 3/2/2020. The price target of $43 was fulfilled within 1 day with a profit of $1.75 (3.91%) receiving and performance score of 39.11.

Average potential price target upside

of $59.7 (63.68%) on ASND (ASCENDIS PHARMA AS).
of $46.87 (29.94%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $24.76 (98.05%) on SDGR (SCHRODINGER).

AKBA Akebia Ther ALNY Alnylam Pharmaceuticals ARQT Arcutis Biotherapeutics ASND Ascendis Pharma AS BPMC Blueprint Medicines Corp GWPH GW Pharmaceuticals plc IONS Ionis Pharmaceuticals IRWD Ironwood Pharmaceuticals KPTI Karyopharm Therapeutics MGNX MacroGenics RYTM Rhythm Pharmaceuticals SDGR Schrodinger SNDX Syndax Pharmaceuticals ZEAL Zealand Pharma A/S ADR AVRO AVROBIO IMRX Immuneering Corp EPZM Epizyme MIRM Mirum Pharmaceuticals NTLA Intellia Therapeutics PLRX Pliant Therapeutics NBRV Nabriva Therapeutics AG BMRN Biomarin Pharmaceutical BBIO BridgeBio Pharma COGT Cogent Biosciences PTCT PTC Therapeutics INCY yte

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ed Arce (HC WAINWRIGHT)